A Phase 3 Multicenter, Double-blind, Randomized, Active Comparator-controlled, Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100mg Once Daily,

StatusActive
Effective start/end date19/12/1431/12/20

Funding

  • Merck Co.: $113,196.03

Keywords

  • Biotechnology & Drug Development, Infectious Diseases